Cytokinetics appoints Sung H. Lee as EVP, CFO effective May 8, 2024

CYTOKINETICS INC

Annual base salary of $550,000; target bonus 45% of base under corporate bonus plan.
Signing bonus of $80,000; repayable if voluntarily resigns or terminated for cause within 12 months.
Initial equity awards: $1,682,500 RSU, $1,682,500 stock options (Black-Scholes), $1,670,000 performance-based PSU.
Lee replaces CEO Robert I. Blum, who had been serving as interim principal financial officer.
Prior roles include CFO at Vir Biotechnology, MorphoSys AG, and Sangamo Therapeutics.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sung H. Lee

Executive Vice President, Chief Financial Officer

CYTK · CYTOKINETICS INC

Effective: 2024-05-08
Filed: April 26, 2024, 7:59 PM ET

On April 23, 2024, Cytokinetics, Incorporated (the “Company”) entered into an employment offer letter (the “Offer Letter”) with Sung H. Lee, pursuant to which Mr. Lee has agreed to serve as the Company’s Executive Vice President (“EVP”), Chief Financial Officer, effective as of May 8, 2024 (the “Start Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sung H. Lee was appointed as Executive Vice President, Chief Financial Officer at CYTOKINETICS INC.

Action: appointed
Role: Executive Vice President, Chief Financial Officer

Exact text from the filing

On April 23, 2024, Cytokinetics, Incorporated (the “Company”) entered into an employment offer letter (the “Offer Letter”) with Sung H. Lee, pursuant to which Mr. Lee has agreed to serve as the Company’s Executive Vice President (“EVP”), Chief Financial Officer, effective as of May 8, 2024 (the “Start Date”).

View on SEC.gov

CYTOKINETICS INC filing history →

Source: SEC EDGAR

accession 0000950170-24-049085

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.